Our study identified cellular and molecular biomarkers, notably CD56, that predict resistance to Rux + Ven, but further work is needed to understand and validate their effect in AML. This trial was registered at www.clinicaltrials.gov as #NCT03874052.

2 days ago

Clinical • P1 data • Journal

NCAM1 (Neural cell adhesion molecule 1) • ITGAM (Integrin, alpha M)

Venclexta (venetoclax) • Jakafi (ruxolitinib)

PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis. (PubMed, Am J Cancer Res)

We identify a link between IL-6 expression and PIM1 expression and activity in human ccRCC tumors and cell lines. Our work provides evidence that targeting an IL-6/JAK/STAT/PIM1 axis may be a viable therapeutic strategy for patients with PIM1-high expressing ccRCC.

2 days ago

Journal

IL6 (Interleukin 6) • PIM1 (Pim-1 Proto-Oncogene)

Jakafi (ruxolitinib)

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)

P1, N=42, Recruiting, City of Hope Medical Center | Suspended --> Recruiting | Trial completion date: Jun 2029 --> Jun 2028 | Trial primary completion date: Jun 2029 --> Jun 2028

2 days ago

Enrollment open • Trial completion date • Trial primary completion date

CXCL9 (Chemokine (C-X-C motif) ligand 9) • MMP3 (Matrix metallopeptidase 3)

Jakafi (ruxolitinib)

ODYSSEY: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (clinicaltrials.gov)

P2, N=68, Recruiting, GlaxoSmithKline | Trial completion date: Nov 2026 --> Mar 2028 | Trial primary completion date: Oct 2026 --> Mar 2027

3 days ago

Trial completion date • Trial primary completion date

Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib)

Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study. (PubMed, Ann Rheum Dis)

The primary endpoint of the SELECT-SWITCH trial was met, with a higher percentage of patients with active RA who switched to upadacitinib after first TNFi failure achieving DAS28-CRP ≤3.2 at 12 weeks than those cycling to a second TNFi, adalimumab, with generally similar safety profiles.

5 days ago

Journal

CRP (C-reactive protein)

methotrexate

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease (clinicaltrials.gov)

P1, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Mar 2032 | Trial primary completion date: Mar 2026 --> Mar 2032

5 days ago

Trial completion date • Trial primary completion date

Jakafi (ruxolitinib)

Up-AA: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (clinicaltrials.gov)

P3, N=1500, Recruiting, AbbVie | Trial completion date: Jan 2028 --> Apr 2030 | Trial primary completion date: Jan 2028 --> Apr 2030

5 days ago

Trial completion date • Trial primary completion date

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (clinicaltrials.gov)

P1/2, N=165, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting

6 days ago

Enrollment open

doxorubicin hydrochloride • cyclophosphamide • golidocitinib (DZD4205)